Truvada

Daily doses of drugs or vaginal gels have proven ineffective at preventing HIV infections in southern Africa, a study out Monday revealed, saying most of the women failed to use them as directed.

A new pill to treat HIV infection -- combining two previously approved drugs plus two new ones -- has been approved for adults living with the virus that causes AIDS, US regulators said.

From a cafe near the go-go bars of a Bangkok red light district where she campaigns for safe sex, Gigi gives an unvarnished view of how she joined Thailand's growing ranks of transgender people with HIV.

Three decades into the AIDS pandemic an end to new infections is in sight, according to Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases.

The UN agency tasked with fighting AIDS on Tuesday welcomed the decision by the United States to allow the use of an HIV prevention pill for the first time.

Authorities were investigating Tuesday how sewing needles ended up in turkey sandwiches on four Delta Air Lines flights, prompting one unsuspecting passenger to be placed on anti-HIV drugs.

The first-ever daily pill to help prevent HIV infection was approved Monday by US regulators for use by healthy adults who are at risk for getting the virus that causes AIDS.

US regulators on Monday approved Truvada, made by Gilead Sciences in California, for use as the first pill to help prevent HIV in some at-risk groups, the US Food and Drug Administration said.

Thirty years into the AIDS epidemic, a cure remains elusive but a growing arsenal of drugs could someday help end new infections, the World Health Organization's HIV/AIDS chief says.

On Monday, the U.S. Food and Drug Administration (FDA) approved Truvada, the first drug to be used for pre-exposure to HIV. On Monday, the U.S. Food and Drug Administration (FDA) approved Truvada, the first drug to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection. Truvada was previously approved by the FDA to be used in combination with other antiretroviral agents for the treatment of HIV-positive adults and children 12 years or older. ?Today's approval marks an important milestone in our fight against HIV,? said FDA Commissioner Margaret A. Hamburg. ?Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease. New treatments as well as prevention methods are needed to fight the HIV epidemic in this country.? Truvada was found to lower the risk of infection by 42 percent compared with place

Thirty years into the AIDS epidemic, a cure remains elusive but a growing arsenal of drugs could someday help end new infections, the World Health Organization's HIV/AIDS chief says.

Thirty years into the AIDS epidemic, a cure remains elusive but a growing arsenal of drugs could someday help end new infections, the World Health Organization's HIV/AIDS chief says.

US health advisors on Thursday urged regulators to approve Truvada, made by Gilead Sciences, as the first preventive pill against HIV/AIDS instead of just as a treatment for infected people.

A US advisory panel on Thursday urged US regulators to approve Truvada by Gilead Sciences as the first pill for prevention of human immunodeficiency virus (HIV).

US health advisors are poised to decide Thursday on whether to recommend the drug, Truvada, as the first preventive pill against AIDS instead of just a treatment for infected people.

Gay men who have five or more sex partners per year are part of a high-risk group that could benefit from a daily pill to ward off HIV, said a cost-benefit analysis by US researchers on Monday.

(Reuters) - Gilead Sciences Inc's four-drug experimental HIV pill worked as well as a regimen containing protease inhibitor Reyataz in the second pivotal trial of the drug, the company said on Monday.

BANGALORE (Reuters) - Gilead Sciences Inc said its four-medicine HIV pill, known as the Quad, worked as well as the company's widely used Atripla three-drug tablet in a late-stage trial.

WASHINGTON (Reuters) - Regulators approved a once-daily HIV pill by Gilead Sciences Inc, giving a new source of revenue to the leading maker of HIV medicines as it faces expiring patents.

Volunteers who responded most to a cocktail of antiretroviral drugs in an HIV prevention trial among gay men had a reduced risk of 92 percent of being infected by the AIDS virus, researchers said on Wednesday.